IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Marvin J. Slepian

Serial No.:

10/072,766

Art Unit:

1633

Filed:

February 8, 2002

Examiner:

Maria Marvich

For:

ENDOMURAL THERAPY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including one (1) page of Form PTO-1449, copies of the two (2) documents cited therein, and a copy of the supplementary European Search Report mailed December 20, 2007 in European Application No. 02704388.4, which corresponds to the above-identified application.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after a Notice of Appeal. The Commissioner is hereby authorized to charge \$180.00, the fee set forth under 37 C.F.R. § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commission is hereby authorized to charge any fees to Deposit Account No. 50-3129.

U.S.S.N.:

10/072,766

Filed:

February 8, 2002

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Foreign Documents

<u>Number</u>	Publication Date	<u>Patentee</u>	<u>Country</u>
WO 97/13463	04-17-1997	Transvascular	PCT
WO 99/18892	04-22-1999	Cambridge Scientific	PCT

U.S.S.N.:

10/072,766

Filed:

February 8, 2002

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has

been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an

independent evaluation of the cited art to determine its relevance to the subject matter of the

present application. Applicant is of the opinion that his claims patentably distinguish over the art

referred to herein, either alone or in combination.

Respectfully submitted,

/ Patrea L. Pabst /

Patrea L. Pabst

Reg. No. 31,284

Dated: March 19, 2008

PABST PATENT GROUP LLP

400 Colony Square, Suite 1200

1201 Peachtree Street

Atlanta, Georgia 30361

(404) 879-2151 (Telephone)

(404) 879-2160 (Fax)

3